Evidence map›Paper›PMID 38524669›Full record

ArticleJHEP reports : innovation in hepatology2024

Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study.

Federica D'Amico, Matteo Rinaldi, Renato Pascale, Marco Fabbrini, Maria Cristina Morelli, Antonio Siniscalchi, Cristiana Laici, Simona Coladonato, Matteo Ravaioli, Matteo Cescon and 5 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Federica D'AmicoMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Matteo RinaldiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Renato PascaleDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Marco FabbriniMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Maria Cristina MorelliInternal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola, Bologna, Italy.
Antonio SiniscalchiDivision of Anesthesiology, Department of Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Cristiana LaiciDivision of Anesthesiology, Department of Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Simona ColadonatoDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Matteo RavaioliGeneral Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola, Bologna, Italy.
Matteo CesconDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Simone AmbrettiMicrobiology Operative Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola, Bologna, Italy.
Pierluigi VialeDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Patrizia BrigidiMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Silvia TurroniUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
Maddalena GiannellaDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITUniversity of Bologna · ITAzienda USL di Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: The aim of this study was to investigate gut microbiome (GM) dynamics in relation to carbapenem-resistant Enterobacterales (CRE) colonization, CRE infection, and non-CRE infection development within 2 months after liver transplant (LT). Methods: A single-center, prospective study was performed in patients undergoing LT from November 2018 to January 2020. The GM was profiled through 16S rRNA amplicon sequencing of a rectal swab taken on the day of transplantation, and fecal samples were collected weekly until 1 month after LT. A subset of samples was subjected to shotgun metagenomics, including resistome dynamics. The primary endpoint was to explore changes in the GM in the following groups: (1) CRE carriers developing CRE infection (CRE_I); (2) CRE carriers not developing infection (CRE_UI); (3) non-CRE carriers developing microbial infection (INF); and (4) non-CRE carriers not developing infection (NEG). Results: Overall, 97 patients were enrolled, and 91 provided fecal samples. Of these, five, nine, 22, and 55 patients were classified as CRE_I, CRE_UI, INF, and NEG, respectively. CRE_I patients showed an immediate and sustained post-LT decrease in alpha diversity, with depletion of the GM structure and gradual over-representation of Conclusions: GM profiling before LT could improve patient stratification and risk prediction and guide early GM-based intervention strategies to reduce infectious complications and improve overall prognosis. Impact and implications: Little is known about the temporal dynamics of gut microbiome (GM) in liver transplant recipients associated with carbapenem-resistant Enterobacterales (CRE) colonization and infection. The GM structure and functionality of patients colonized with CRE and developing infection appeared to be distinct compared with CRE carriers without infection or patients with other microbial infection or no infection and CRE colonization. Higher proportions of antimicrobial-resistant pathogens and poor representation of bacteria and metabolic pathways capable of promoting overall host health were observed in CRE carriers who developed infection, even before liver transplant. Therefore, pretransplant GM profiling could improve patient stratification and risk prediction and guide early GM-based intervention strategies to reduce infectious complications and improve overall prognosis.

Indexed as

Antibiotic resistanceCarbapenem-resistant EnterobacteralesGut microbiomeGut resistomeLiver transplant

Identifiers

PMID38524669
PMCPMC10960129
OpenAlexW4391749688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.